Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition and immune responses, and various environmental factors. Despite many treatment options, there is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term treatment options have resulted in a substantial economic burden to the healthcare system worldwide. Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies excluding their biosimilars approved by the US Food and Drug Administration for induction and maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently available drugs, especially biologics, is the main challenge in IBD management. Natural products have significant potential as therapeutic agents with an increasing role in health care. Given that natural products display great structural diversity and are relatively easy to modify chemically, they represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the pathology, currently available treatment options for IBD and associated challenges, and the roles played by natural products in health care. It discusses these natural products within the current biodiscovery research agenda, including the applications of drug discovery techniques and the search for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 2×
“Diet influences the composition of the microbiota and their metabolic activity in the human gut [86].”
BackgroundDiversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513
Hay fever, hygiene, and household size.
Strachan, D. P. (1989) · BMJ · doi:10.1136/bmj.299.6710.1259 · Cited by 5,054 · cited 1×
“Strachan first proposed the Hygiene Hypothesis in 1989 to explain the increasing incidence of atopy (allergic disorders) [55].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 2×
“eno e- ide association studies identified 163 susceptible gene loci in IB ( ith 110 co on, 30 C specific, and 23 UC specific) [62], highlighting the role of genetics in IBD pathogenesis.”
BackgroundRecognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251 · cited 1×
“The commensal human gut microbiota is essential for maintaining intestinal epithelial homeostasis and protection from mucosal injury [79].”
BackgroundMulti-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143
The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058 · cited 2×
“There is a growing concern that the western diet, rich in fats and sugars, is responsible for the change in the diversity and metabolic activity of human gut microbiota, thereby contributing to the increasing incidence of IBD [87,88].”
BackgroundDysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., Sadeghi, A., Nixon, M. R., Abdoli, A., Abolhassani, H., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30333-4 · Cited by 2,313
Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice
Devkota, S., Wang, Y., Musch, M. W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D. A., Jabri, B., & Chang, E. B. (2012) · Nature · doi:10.1038/nature11225 · Cited by 1,904
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741 · cited 3×
“A study involving 136 Japanese IBD patients found sleep disturbances as a potential risk factor of disease flare-up for both UC and CD within one year [95], but a similar kind of study (3173 IBD patients with sleep disturbances) conducted by Ananthakrishnan et al. [101] could observe an increased risk of disease flare…”
BackgroundLow counts of Faecalibacterium prausnitzii in colitis microbiota
Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P., & Doré, J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20903 · Cited by 1,275 · cited 1×
“Firmicutes species, such as Faecalibacterium prausnitzii, has been reported to be poorly represented in patients with active IBD compared to healthy subjects [84].”
BackgroundFaubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Jess, T., Rungoe, C., & Peyrin–Biroulet, L. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.010 · Cited by 958 · cited 2×
“4-f l i er i atie ts it , a t e risk is ig er i ales t a fe ales a for t ose iag ose it a exte si e colitis at a yo g a e [31].”
BackgroundNg, S. C., Tang, W., Ching, J. Y., Wong, M., Chow, C. M., Hui, A. J., Wong, T. C., Leung, V. K., Tsang, S. W., Yu, H. H., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.04.007 · Cited by 830
Trichuris suis therapy in Crohn’s disease
Summers, R. W., Elliott, D. E., Urban, J. F., Thompson, R., & Weinstock, J. V. (2005) · Gut · doi:10.1136/gut.2004.041749 · Cited by 762
Transdermal Nicotine for Active Ulcerative Colitis
Pullan, R. D., Rhodes, J., Ganesh, S., Mani, V., Morris, J. S., Williams, G. T., Newcombe, R. G., Russell, M., Feyerabend, C., Thomas, G., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301202 · Cited by 505 · cited 1×
“Additionally, the transdermal treatment of active UC patients with nicotine patches also showed better remission compared to the placebo group [94].”
MethodStress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission
Levenstein, S., Prantera, C., Varvo, V., Scribano, M. L., Andreoli, A., Luzi, C., Arcà, M., Berto, E., Milite, G., & Marcheggiano, A. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02012.x · Cited by 451 · cited 1×
“A positive correlation between psychological distress and IBD flare-ups [102,103] indicates the need for timely psychological therapy in IBD patients.”
BackgroundNg, S. C., Tang, W., Leong, R. W., Chen, M., Ko, Y., Studd, C., Niewiadomski, O., Bell, S., Kamm, M. A., de Silva, H. J., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307410 · Cited by 443
Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules
Maizels, R. M., Smits, H. H., & McSorley, H. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.016 · Cited by 435
European evidence based consensus on surgery for ulcerative colitis
Øresland, T., Bemelman, W. A., Sampietro, G. M., Spinelli, A., Windsor, A., Ferrante, M., Marteau, P., Zmora, O., Kotze, P. G., Espin-Basany, E., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.012 · Cited by 353
Mikocka-Walus, A., Pittet, V., Rossel, J.-B., von Känel, R., Anderegg, C., Bauerfeind, P., Beglinger, C., Begré, S., Belli, D., Bengoa, J. M., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.045 · Cited by 348 · cited 2×
“Studies have shown that poor mental health is associated with disease flares and a generally poorer IBD prognosis [97,222].”
BackgroundOral budesonide is as effective as oral prednisolone in active Crohn’s disease
Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.-G., & the Global Budesonide Study Group (1997) · Gut · doi:10.1136/gut.41.2.209 · Cited by 324
Role of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315 · cited 1×
“The human lower GI tract has 1014 microbial cells [80], and Bacteriodetes and Firmicutes are the two most dominant phyla in the gut [81].”
BackgroundMartín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., Verdu, E. F., Bercik, P., Bermúdez-Humarán, L. G., & Langella, P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000440815.76627.64 · Cited by 284 · cited 1×
“prausnitzii significantly decreased the severity of colitis in the trinitrobenzene sulfonic acid (TNBS)-induced mouse model of colitis [85].”
BackgroundBenchimol, E. I., Mack, D. R., Guttmann, A., Nguyen, G. C., To, T., Mojaverian, N., Quach, P., & Manuel, D. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.52 · Cited by 258 · cited 2×
“at a younger age have an increased risk of IBD [75].”
BackgroundKaplan, G. G., & Ng, S. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30077-2 · Cited by 240
Mardini, H. E., Kip, K. E., & Wilson, J. W. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000020509.23162.cc · Cited by 211 · cited 1×
“A positive correlation between psychological distress and IBD flare-ups [102,103] indicates the need for timely psychological therapy in IBD patients.”
BackgroundIL-9 and its receptor are predominantly involved in the pathogenesis of UC
Nalleweg, N., Chiriac, M. T., Podstawa, E., Lehmann, C., Rau, T. T., Atreya, R., Krauss, E., Hundorfean, G., Fichtner-Feigl, S., Hartmann, A., et al. (2015) · Gut · doi:10.1136/gutjnl-2013-305947 · Cited by 181
Depression is associated with more aggressive inflammatory bowel disease
Kochar, B., Barnes, E. L., Long, M. D., Cushing, K. C., Galanko, J., Martin, C. F., Raffals, L. E., & Sandler, R. S. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.423 · Cited by 178
Yen, H.-H., Weng, M.-T., Tung, C.-C., Wang, Y.-T., Chang, Y. T., Chang, C.-H., Shieh, M.-J., Wong, J.-M., & Wei, S.-C. (2019) · Intestinal Research · doi:10.5217/ir.2018.00096 · Cited by 139
Heller, F., Fromm, A., Gitter, A. H., Mankertz, J., & Schulzke, J.-D. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.46 · Cited by 135 · cited 2×
“IL-13 also disturbs the membrane integrity by increasing the rate of cell apoptosis (which intensifies upon exposure to TNF-α), and by changing the protein composition of the tight junctions [38].”
BackgroundLerebours, E., Gower-Rousseau, C., Merle, V., Brazier, F., Debeugny, S., Marti, R., Salomez, J. L., Hellot, M. F., Dupas, J. L., Colombel, J. F., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00931.x · Cited by 130
A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s disease
Schölmerich, J., Fellermann, K., Seibold, F. W., Rogler, G., Langhorst, J., Howaldt, S., Novacek, G., Petersen, A. M., Bachmann, O., Matthes, H., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw184 · Cited by 66
Mikocka‐Walus, A., Massuger, W., Knowles, S. R., Moore, G. T., Buckton, S., Connell, W., Pavli, P., Raven, L., & Andrews, J. M. (2020) · JGH Open · doi:10.1002/jgh3.12236 · Cited by 55
Wangchuk, P., Shepherd, C., Constantinoiu, C., Ryan, R. Y. M., Kouremenos, K. A., Becker, L., Jones, L., Buitrago, G., Giacomin, P., Wilson, D., et al. (2019) · Infection and Immunity · doi:10.1128/iai.00851-18 · Cited by 42
Self-citation
Cited by
Cross-scale multi-instance learning for pathological image diagnosis
Deng, R., Cui, C., Remedios, L. W., Bao, S., Womick, R. M., Chiron, S., Li, J., Roland, J. T., Lau, K. S., Liu, Q., et al. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103124 · Cited by 95
Metadata
- Authors
- Yeshi, K., Ruscher, R., Hunter, L., Daly, N. L., Loukas, A., & Wangchuk, P.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-04-28
- Volume
- 9
- Issue
- 5
- Pages
- 1273
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3021474821
- Cited by
- 184
- References
- 39
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.